These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28234746)

  • 1. Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients.
    Liu D; Seyboth B; Mathew S; Gilheeney SW; Chou AJ; Drill E; Kobos R
    J Pediatr Hematol Oncol; 2017 May; 39(4):e177-e182. PubMed ID: 28234746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM; Lenz KL
    Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
    Beaven AW; Shea TC
    Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
    Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
    Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
    Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
    Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
    Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
    Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
    Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis.
    Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
    Anticancer Res; 2014 Dec; 34(12):7379-82. PubMed ID: 25503176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
    N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
    Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
    Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
    Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
    J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications.
    Vadhan-Raj S; Goldberg JD; Perales MA; Berger DP; van den Brink MR
    J Cell Mol Med; 2013 Nov; 17(11):1371-84. PubMed ID: 24251854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
    Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
    J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
    Radtke ML; Kolesar JM
    J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
    Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.
    Kobbe G; Bruns I; Schroeder T; Czibere A; Warnecke J; Hieronimus N; Safaian N; Kondakci M; Saure C; Germing U; Haas R; Fenk R
    Ann Oncol; 2010 Sep; 21(9):1898-1904. PubMed ID: 20233744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.